Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
756 stopped studies mapped to Acute Leukemia and descendants · 89% state a reason
Over the 756 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | Phase 2 | terminated | Jan 30, 2015 | Pharmacyclics LLC. | Study data do not support development in AML. | Other (stated, no rule matched) |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an… | N/A | terminated | May 15, 2012 | Memorial Sloan Kettering Cancer Center | Closed due to poor accrual | Enrollment / accrual |
| NCT00900445 | Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk… | — | withdrawn | May 12, 2009 | Children's Oncology Group | not stated | Not stated |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia…(AML/MDS) | Phase 1 / Phase 2 | terminated | Feb 21, 2013 | Biosuccess Biotech Co., Ltd. | Difficulty of patient enrollment | Enrollment / accrual |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic…(AHCTALL) | Phase 2 | terminated | Dec 23, 2009 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia…(ATLAS2015) | — | terminated | Apr 28, 2015 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult… | Phase 1 | terminated | Jul 29, 2013 | ERYtech Pharma | Sponsor decision based off site/PI feedback about | Sponsor / business decision |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2015 | Wake Forest University Health Sciences | Drug Supply Issues | Drug supply |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | Phase 2 | withdrawn | Mar 8, 2012 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT02532010 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML(Pacritinib) | Phase 2 | terminated | Aug 25, 2015 | Weill Medical College of Cornell University | The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to… | Funding |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | — | terminated | Mar 31, 2011 | National Cancer Institute (NCI) | A replacement protocol was created to replace this current version of protocol. | Other (stated, no rule matched) |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | Phase 2 | withdrawn | Jul 14, 2010 | Stanford University | no accrual | Enrollment / accrual |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | withdrawn | Apr 18, 2013 | Stanford University | not stated | Not stated |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | Phase 1 / Phase 2 | terminated | Sep 6, 2010 | University College, London | Due to lack of biological efficacy and CD19 CAR CTL persistence | Efficacy / futility |
| NCT02635074 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Dec 18, 2015 | Steven E. Coutre | safety | Safety / toxicity |
| NCT02848248 | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Jul 28, 2016 | Seagen Inc. | not stated | Not stated |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Phase 2 | withdrawn | Mar 30, 2016 | Stanford University | Logistical and administrative issues | Other (stated, no rule matched) |
| NCT02905994 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | Phase 1 | withdrawn | Sep 19, 2016 | Massachusetts General Hospital | Funding Withdrawn | Funding |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT02680951 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor… | Phase 1 | withdrawn | Feb 12, 2016 | Emory University | Withdrawn due to lack of participants. | Other (stated, no rule matched) |
| NCT02462265 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid… | Phase 2 | suspended | Jun 4, 2015 | Oshadi Drug Administration | not stated | Not stated |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | Phase 2 | terminated | Jan 15, 2008 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT01770158 | Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute… | — | terminated | Jan 17, 2013 | University of Ulm | Recruitment goal cannot be achieved any more as only 8 patients have been recruited since start of… | Enrollment / accrual |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | Phase 2 | terminated | Jul 25, 2013 | National Cancer Institute (NCI) | Lack of efficacy. | Efficacy / futility |
| NCT02519712 | Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized… | N/A | terminated | Aug 11, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02204020 | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165) | Phase 2 | withdrawn | Jul 30, 2014 | University of Pittsburgh | Lack of interest with investigators - no subjects enrolled | Enrollment / accrual |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine:… | Phase 2 | withdrawn | Oct 21, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged… | Phase 2 | terminated | Apr 17, 2015 | St. Jude Children's Research Hospital | Accrual goals were no longer feasible based on restrictions imposed by the DSMB. | Enrollment / accrual |
| NCT03347994 | Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | withdrawn | Nov 20, 2017 | Justin Watts | Discordance in contractual language and terms. | Other (stated, no rule matched) |
| NCT02198482 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly… | Phase 2 | terminated | Jul 23, 2014 | University of Ulm | development program of study drug volasertib was stopped by Boehringer Ingelheim due to… | Drug supply |
| NCT02631252 | Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for… | Phase 1 | terminated | Dec 16, 2015 | Alison Sehgal, MD, MS | Inability to accrue | Enrollment / accrual |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic… | Phase 2 | terminated | Sep 13, 2012 | MorphoSys AG | not stated | Not stated |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT02578511 | Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With… | Phase 1 | withdrawn | Oct 19, 2015 | Ehab L Atallah | No enrollment, another competing study and difficult to find the right person to enroll on this… | Enrollment / accrual |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML…(SAFEGUARD) | Phase 1 / Phase 2 | withdrawn | Aug 4, 2016 | F2G Ltd | study no longer required | Other (stated, no rule matched) |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml…(SAFEGUARDFP) | Phase 1 / Phase 2 | withdrawn | Jan 30, 2017 | F2G Ltd | Study no longer required | Other (stated, no rule matched) |
| NCT02335814 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Jan 12, 2015 | RAPT Therapeutics, Inc. | Dose escalation completed; Sponsor decision | Sponsor / business decision |
| NCT02815059 | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and… | Phase 1 | withdrawn | Jun 28, 2016 | University of Utah | Termination of Investigator Initiated Studies using Ibrutinib | Investigator |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT00583102 | Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory… | Phase 1 / Phase 2 | terminated | Dec 31, 2007 | University of Iowa | Slow accrual, PI left institution | Investigator |
| NCT01442714 | Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk… | Phase 2 | terminated | Sep 28, 2011 | Stanford University | Lack of efficacy - Inability to meet the primary response endpoint | Efficacy / futility |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic… | Phase 2 | terminated | Mar 11, 2011 | Masonic Cancer Center, University of Minnesota | Slow accrual | Enrollment / accrual |
| NCT01464359 | T-Cell Depleted Double UCB for Refractory AML | Phase 2 | terminated | Nov 3, 2011 | Masonic Cancer Center, University of Minnesota | Slow accrual | Enrollment / accrual |
| NCT02049801 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or… | Phase 1 | terminated | Jan 30, 2014 | Bruno C. Medeiros | logistics | Other (stated, no rule matched) |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | Phase 2 / Phase 3 | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | Replaced by a different study | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 14, 2018source: clinicaltrials